Core Promoter Mutations, Viral Replication and Liver Damage Are Not Related with Each Other in Chronic Hepatitis B Infection

2000 ◽  
Vol 28 (5) ◽  
pp. A211-A211
Author(s):  
F. Hong ◽  
Y. K. Chun ◽  
J. Ha ◽  
S. S. Kim
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Viral Replication ◽  
Chronic Hepatitis B ◽  
Liver Damage ◽  
Core Promoter ◽  
Hepatitis B Infection ◽  
Chronic Hepatitis B Infection ◽  
Promoter Mutations

scholarly journals [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

2015 ◽  
Vol 9 (4) ◽  
pp. 95-100
Author(s):  
Fabio Tarsetti ◽  
Giuseppe Tarantino ◽  
Piergiorgio Mosca ◽  
Emidio Scarpellini ◽  
Giammarco Fava
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Hepatitis B ◽  
Viral Replication ◽  
Chronic Hepatitis B ◽  
Genetic Resistance ◽  
Abdominal Ultrasound ◽  
Current Treatment ◽  
Hepatitis B Infection ◽  
Chronic Hepatitis B Infection

BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir.MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered.RESULTS: After 12 weeks of therapy, entecavir and tenofovir lead to HBV-DNA negativization in 44% and 62% of patients, respectively. A case of viral seroconversion for HBeAg and HBsAg was evident in entecavir group, while no cases were registered in tenofovir group. After 12 weeks, 11% of entecavir treated patients and 37% of tenofovir treated patients showed normalization of transaminases.DISCUSSION: Tenofovir seems to exert a better viral replication inhibition (though not statistically significant) and to show transaminases improvement in comparison with entecavir, which, in turn, results more effective in HBeAg/HBsAg seroconversion. Both drugs have a high safety profile in terms of side effects.[Article in Italian]

Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection

1997 ◽  
Vol 12 (9-10) ◽  
pp. S354-S369 ◽  
Author(s):  
JR WANDS ◽  
M GEISSLER ◽  
JZU PUTLITZ ◽  
H BLUM ◽  
F WEIZSÄCKER ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Chronic Hepatitis ◽  
Nucleic Acid ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis B Infection ◽  
Chronic Hepatitis B Infection

scholarly journals Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection

2010 ◽  
Vol 9 (2) ◽  
pp. 194-197 ◽  
Author(s):  
Akif Altinbaş ◽  
llhami Yüksel ◽  
Melih Pamukcu ◽  
Fuat Ekiz ◽  
Ömer Başar ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis B Infection ◽  
Chronic Hepatitis B Infection ◽  
Hbsag Seroconversion
Sign in / Sign up

Export Citation Format

Share Document